Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACP3 | P15309 | 3/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
| ▸ | LAP3 | P28838 | 3/20 | 0.39 |
| ▸ | ANPEP | P15144 | 1/20 | 0.39 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.39 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3234324 | 0.79 | ACP3 (0.54) | ACP3SMN1; SMN2ANPEP | |
| SCHEMBL779167 | 0.77 | CYP3A4 (0.44) | ACP3SRCLAP3ANPEPCYP1A2 | |
| SCHEMBL3884606 | 0.77 | ACP3 (0.61) | ACP3SRCLAP3ANPEPCYP1A2 | |
| SCHEMBL3233327 | 0.76 | ACP3 (0.51) | ACP3SMN1; SMN2ANPEPMAPTNPSR1 | |
| SCHEMBL21638769 | 0.76 | ACP3 (0.59) | ACP3SMN1; SMN2SRCAOC3LMNA | |
| SCHEMBL21616480 | 0.74 | ACP3 (0.53) | ACP3SMN1; SMN2LAP3ANPEPAOC3 | |
| SCHEMBL875769 | 0.73 | SRC (0.60) | ACP3SRCLAP3ANPEP | |
| SCHEMBL11402377 | 0.71 | ACP3 (0.47) | ACP3SRCLAP3ANPEP | |
| SCHEMBL11058548 | 0.71 | MEN1 (0.45) | ACP3AOC3ADRB2ADRB1 | |
| SCHEMBL777640 | 0.69 | SRC (0.46) | ACP3SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140073608-A1 | Butyrylcholinesterase Inhibitors | MGP BIOTECHNOLOGIES, LLC (US) | 2014-03-13 | — | — | US | disclosed |
| US-20100069337-A1 | BUTYRYLCHOLINESTERASE INHIBITORS | JAL THERAPEUTICS, LLC | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140073608-A1 | Butyrylcholinesterase Inhibitors | BCHE, ACHE, PSEN1 | ACP3 261/4885SMN1; SMN2 178/4885SRC 2662/4885 |
| US-20100069337-A1 | BUTYRYLCHOLINESTERASE INHIBITORS | BCHE, ACHE, PSEN1 | ACP3 261/4885SMN1; SMN2 178/4885SRC 2662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.